Nicox S.A. (EPA:ALCOX)

Market Cap	36.57M +70.4%
Revenue (ttm)	3.32M -63.4%
Net Income	-27.06M
EPS	-0.37
Shares Out	88.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	619,648
Average Volume	758,688
Open	0.4200
Previous Close	0.4170
Day's Range	0.4100 - 0.4285
52-Week Range	0.2000 - 0.6500
Beta	0.29
RSI	65.66
Earnings Date	Apr 21, 2026

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2024, Nicox's revenue was 7.86 million, an increase of 13.84% compared to the previous year's 6.90 million. Losses were -22.39 million, 7.23% more than in 2023.